Associated Papers
Chromatin Remodulator CHD4: A Potential Target for Cancer Interception.
Goswami K et al.
Genes, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A et al.
Journal of Hematology & Oncology, 2024
CHD4 R975H mutant activates tumorigenic pathways and promotes stemness and M2-like macrophage polarization in endometrial cancer.
Zhang Q et al.
Scientific Reports, 2024
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Mutational landscape of cancer-driver genes across human cancers.
Sinkala M
Scientific Reports, 2023
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.
Charo LM et al.
Molecular Oncology, 2021
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A et al.
Cancer Medicine, 2021
Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer.
Novillo A et al.
Frontiers in Oncology, 2021
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.
Mateo L et al.
Genome Medicine, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Systematic analysis of the intersection of disease mutations with protein modifications.
Simpson CM et al.
Bmc Medical Genomics, 2019
Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.
Fennell L et al.
Cellular and Molecular Gastroenterology and Hepatology, 2019
The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response.
Zhang J et al.
Journal of Cancer Research and Cellular Therapeutics, 2019
CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling.
Li Y et al.
American Journal of Cancer Research, 2018
Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer.
Gnad F et al.
Bmc Genomics, 2015